Treatment for relapsed acute lymphoblastic leukemia (ALL) in children and young adults continues to evolve. Despite optimization of cytotoxic chemotherapeutic approaches risk-adapted therapy, about 12% pediatric patients still relapse, survival rates this population remain poor. Salvage therapy be challenging as attempts further intensify chemotherapy have resulted excessive toxicity without im...